Thus, we propose that the combined administration of crizanlizumab, a humanized anti–P selectin antibody licensed as a treatment option for VOC, and CSF-1 may yield even greater efficacy in SCD management. This evidence concerns the gene SELP and Schnyder corneal dystrophy.